- Home
- JPI vs VNDA Comparison
JPI vs VNDA Comparison
Compare JPI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPI
- VNDA
- Stock Information
- Founded
- JPI 2012
- VNDA 2002
- Country
- JPI United States
- VNDA United States
- Employees
- JPI N/A
- VNDA N/A
- Industry
- JPI Finance Companies
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- JPI Finance
- VNDA Health Care
- Exchange
- JPI Nasdaq
- VNDA Nasdaq
- Market Cap
- JPI 278.6M
- VNDA 237.9M
- IPO Year
- JPI N/A
- VNDA 2006
- Fundamental
- Price
- JPI $19.34
- VNDA $4.33
- Analyst Decision
- JPI
- VNDA Strong Buy
- Analyst Count
- JPI 0
- VNDA 2
- Target Price
- JPI N/A
- VNDA $16.50
- AVG Volume (30 Days)
- JPI 54.7K
- VNDA 754.6K
- Earning Date
- JPI 01-01-0001
- VNDA 05-07-2025
- Dividend Yield
- JPI 6.15%
- VNDA N/A
- EPS Growth
- JPI N/A
- VNDA N/A
- EPS
- JPI N/A
- VNDA N/A
- Revenue
- JPI N/A
- VNDA $198,772,000.00
- Revenue This Year
- JPI N/A
- VNDA $14.36
- Revenue Next Year
- JPI N/A
- VNDA $44.53
- P/E Ratio
- JPI N/A
- VNDA N/A
- Revenue Growth
- JPI N/A
- VNDA 3.18
- 52 Week Low
- JPI $16.02
- VNDA $3.85
- 52 Week High
- JPI $19.12
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- JPI 52.28
- VNDA 43.42
- Support Level
- JPI $17.95
- VNDA $4.27
- Resistance Level
- JPI $20.40
- VNDA $4.46
- Average True Range (ATR)
- JPI 0.66
- VNDA 0.22
- MACD
- JPI 0.08
- VNDA 0.01
- Stochastic Oscillator
- JPI 66.88
- VNDA 54.55
About JPI Nuveen Preferred and Income Term Fund of Beneficial Interest
Nuveen Preferred and Income Term Fund is a closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The company's products include mutual funds, closed-end funds, Exchange-traded funds, Multi-asset model portfolios, and others.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.